- Home
- IMCR
as 06-20-2025 4:00pm EST
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | OXFORDSHIRE |
| Market Cap: | 1.5B | IPO Year: | 2021 |
| Target Price: | $58.13 | AVG Volume (30 days): | 560.7K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.15 - $41.54 | Next Earning Date: | 08-07-2025 |
| Revenue: | $333,581,000 | Revenue Growth: | 25.75% |
| Revenue Growth (this year): | 26.82% | Revenue Growth (next year): | 8.15% |
Latest Immunocore Holdings plc News
IMCR Breaking Stock News: Dive into IMCR Ticker-Specific Updates for Smart Investing
Zacks
19 days ago
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet
GlobeNewswire
19 days ago
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
MT Newswires
25 days ago
Deutsche Bank Initiates Immunocore Holdings at Buy With $65 Price Target
Zacks
a month ago
Is it a Good Idea to Invest in Immunocore Stock Right Now?
MT Newswires
a month ago
Oppenheimer Adjusts Price Target on Immunocore Holdings to $86 From $85, Maintains Outperform Rating
MT Newswires
a month ago
Sector Update: Health Care Stocks Gain Wednesday Afternoon
Zacks
a month ago
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics
MT Newswires
a month ago
Immunocore Holdings' Q1 Swings to Net Income, Revenue Rises
Compare IMCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMCR Immunocore Holdings plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.